Clinical Trials Epilepsy Media Treatment 
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
The Cannigma
MAY 19, 2021
This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. 2021.108514.
Cannabis Law Report
AUGUST 21, 2019
Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.
MMJ Recs
DECEMBER 22, 2023
The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.
Cannabis Law Report
DECEMBER 8, 2021
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Cannabis Law Report
SEPTEMBER 24, 2019
T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.
Expert insights. Personalized for you.
52 
Let's personalize your content